Medivation Investors: Why Your Stock Just Jumped 140%

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Ah, the irony. Just hours after Dendreon (Nasdaq: DNDN  ) released a disappointing quarterly update on its prostate cancer vaccine Provenge, small biotech Medivation (Nasdaq: MDVN  ) showed the market how it's done .

How? By announcing the late-stage trial results for its prostate cancer drug candidate MDV3100. And they rock. Patients lived on average five months longer taking the oral medication than the placebo, and side effects were reportedly mild.

MDV3100 looks to be a blockbuster in the making. With roughly one out of six men expected to be diagnosed with prostate cancer in their lifetimes, there are plenty of patients to go around. But biotechs with their own candidates -- Exelixis' (Nasdaq: EXEL  ) cabozantinib comes to mind -- need to be watching what happens here carefully.

And Dendreon really needs to watch its backside here. Provenge is a first-line treatment, but it's having a hard time gaining traction with doctors. Management claims real progress in educating about the Medicare reimbursement for the $90,000 treatment, but knowledge doesn't equal sales. And it may not stop doctors from prescribing MDV3100 off label. If there have been light concerns over Johnson & Johnson's (NYSE: JNJ  ) Zytiga and its encroachment on Provenge's turf, then Dendreon investors are furrowing their brows harder tonight.

For Medivation investors looking for more possible share-pops, the findings of another trial named PREVAIL -- in which MDV3100 is tested in men who have not yet received therapy -- is expected soon, not to mention an important meeting with the FDA next year.

David Williamson owns shares of Dendreon and Johnson & Johnson, but he holds no other position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson, Dendreon, and Exelixis. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Exelixis and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1583648, ~/Articles/ArticleHandler.aspx, 10/21/2016 11:39:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,074.19 -88.16 -0.49%
S&P 500 2,136.15 -5.19 -0.24%
NASD 5,250.66 8.83 0.17%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
EXEL $11.70 Down -0.04 -0.34%
Exelixis CAPS Rating: ****
JNJ $113.33 Down -1.54 -1.34%
Johnson and Johnso… CAPS Rating: ****
MDVN $0.00 Down +0.00 +0.00%
Medivation CAPS Rating: ****